Although multiple studies have explored the potential roles of T-DM1 in the treatment of HER2 expressing gastric, gastroesophageal, colorectal, lung, and other cancers, it has not been approved for any non-breast malignancies yet [6,16,25-28]. This evidence concerns the gene ERBB2 and cancer.